Cardinal Health (NYSE:CAH) received a $73.00 price objective from investment analysts at Mizuho in a research report issued on Wednesday. The brokerage currently has a “hold” rating on the stock. Mizuho’s price target would suggest a potential downside of 2.26% from the stock’s previous close.
Several other equities research analysts also recently weighed in on CAH. Robert W. Baird restated a “hold” rating and set a $80.00 price target on shares of Cardinal Health in a report on Wednesday, January 17th. Evercore ISI assumed coverage on Cardinal Health in a report on Thursday, January 4th. They set an “in-line” rating and a $67.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Cardinal Health in a report on Thursday, October 12th. Jefferies Group cut their price target on Cardinal Health from $77.00 to $67.00 and set a “hold” rating on the stock in a report on Tuesday, November 7th. Finally, ValuEngine downgraded Cardinal Health from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $73.83.
Cardinal Health (CAH) traded up $1.48 during mid-day trading on Wednesday, hitting $74.69. The company had a trading volume of 2,770,000 shares, compared to its average volume of 3,160,000. The company has a debt-to-equity ratio of 1.35, a current ratio of 1.06 and a quick ratio of 0.52. Cardinal Health has a 52-week low of $54.66 and a 52-week high of $84.88. The stock has a market cap of $23,540.00, a P/E ratio of 21.78, a PEG ratio of 1.69 and a beta of 0.85.
In other news, CEO Michael C. Kaufmann sold 18,586 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $73.90, for a total value of $1,373,505.40. Following the transaction, the chief executive officer now owns 211,849 shares in the company, valued at approximately $15,655,641.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.97% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FDx Advisors Inc. increased its holdings in shares of Cardinal Health by 7.9% in the 3rd quarter. FDx Advisors Inc. now owns 43,508 shares of the company’s stock valued at $2,912,000 after acquiring an additional 3,172 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Cardinal Health by 77.8% in the 3rd quarter. Janus Henderson Group PLC now owns 108,930 shares of the company’s stock valued at $7,291,000 after purchasing an additional 47,669 shares during the period. Cadence Capital Management LLC boosted its position in shares of Cardinal Health by 8.4% in the 3rd quarter. Cadence Capital Management LLC now owns 65,205 shares of the company’s stock valued at $4,364,000 after purchasing an additional 5,078 shares during the period. Commonwealth Equity Services Inc boosted its position in shares of Cardinal Health by 7.4% in the 3rd quarter. Commonwealth Equity Services Inc now owns 72,959 shares of the company’s stock valued at $4,882,000 after purchasing an additional 5,011 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in shares of Cardinal Health by 4.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 824,347 shares of the company’s stock valued at $55,165,000 after purchasing an additional 36,534 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.
Cardinal Health Company Profile
Cardinal Health, Inc is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies.
